AdvanCell

Cut Through Quarterly 3Q 2026

Cut Through Venture's quarterly report records a record $4.2 billion raised across 78 Australian venture rounds in Q3 2026, dominated by Firmus's $2.85 billion data centre raise, with sector trends, valuations and investor sentiment.

Also Startup Daily

Brandon Capital's $60m taypayer-funded biotech bets

Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.

Also australiatimes.com

Brisbane biotech AdvanCell just raised a record $450 million

Brisbane radiopharmaceutical developer AdvanCell has closed an oversubscribed Series D round, led by Ally Bridge Group and Alpha Wave with several institutional investors returning, to fund late-stage prostate cancer trials and US manufacturing.

Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close totalling over A$430 m

Brandon Capital has completed a A$439 million final close for its sixth life sciences fund, bringing the National Reconstruction Fund Corporation and WA Government in alongside backers such as HESTA, Hostplus, CSL and QIC.

2025 state of raising: $1.8 billion in – as late-stage deals boom

Tracxn figures show Australian tech funding reached $1.8 billion by mid-2025, powered by large late-stage rounds at Protecht, Airwallex, Harrison AI and Advancell, while seed and early-stage raising fell away sharply.

Cancer treatment biotech AdvanCell injects $178 million Series C

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

Sydney cancer-therapy developer AdvanCell has completed a US$112 million Series C that was oversubscribed, co-led by four investors, with Brandon Capital among new backers; three investor representatives join the board.

Also Startup Daily·SmartCompany·Forbes Australia

Brandon Capital news

Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Cut Through Venture·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·Forbes Australia·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com·Forbes Australia